NEW HAVEN, Conn., Sept. 10 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, today announced that seven posters have been accepted for presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in San Francisco, CA on September 12-15, 2009. Details on these presentations are as follows:
Location/ Poster/ Date Time Session Title Presentation Sept. 13 11:15am- Oxazolidinones In Vitro Activity of Hall B 1:15pm Radezolid against MRSA Poster #277 Causing Skin and Wound Present- Infections from the ation United States, Europe, #E-810 and Asia Sept. 13 11:15am- New Research Novel Antibiotic Classes Hall B 1:15pm Technologies to Treat Gram-Negative Poster #332 and Infections Present- Methodologies ation #F2-861 Sept. 14 11:15am- Antibiotic Anti-MRSA Properties of Hall B 1:15pm Resistance in Delafloxacin: Mutant Poster #101 Staphylococcus Analysis and Present- aureus Characterization ation #C1-1363 Sept. 15 9:00am- PK/PD Clinical Trial Dose Hall D 11:00am Investigational Selection for Poster #15 Antibacterials Delafloxacin (DFX) for Present- Complicated Skin and ation Skin-Structure #A1-1942 Infections (cSSSI) Sept. 15 9:00am- New Macrolides Enhanced Macrolides: Hall D 11:00am and Ketolides Optimized Molecular Poster #125 Properties for Oral Present- Exposure ation #F1-2049 Sept. 15 9:00am- New Macrolides Enhanced Macrolides: Hall D 10:00am and Ketolides Overcoming Resistance Poster #126 by Improving Target Present- Affinity ation #F1-2050 Sept. 15 9:00am- PK/PD Pharmacokinetics and Hall D 11:00am Investigational Pharmacodynamics of Poster #14 Antibacterials Delafloxacin in S. Present- aureus Murine Thigh ation Infection Models #A1-1941
"It is very satisfying to present for critical review the scientific developments Rib-X has fostered during the past year and in four distinctive antibiotic programs. It is especially rewarding to receive input from our peers at the premier anti-infective conference," said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. "We are particularly pleased to present proof-of-concept data on our novel chemical class Gram-negative program."
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections has completed two Phase 2 trials and the Rx-02 discovery program which is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late stage clinical trials.
For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.
For further information please contact:
Media: Irma Gomez-Dib FD Life Sciences Tel: 212-850-5761 email@example.com Investors: John Capodanno FD Life Sciences Tel: 212-850-5705 John.firstname.lastname@example.org
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved